Covid-19: BioNTech, Pfizer say 3 vaccine doses neutralise Omicron variant

BioNTech and Pfizer said on Wednesday a three-shot course of their Covid-19 vaccine was shown to generate a neutralising effect against the new Omicron variant in a laboratory test.

In the first official statement from vaccine manufacturers on the likely efficacy of their shot against Omicron, BioNTech and Pfizer said in a joint statement that two vaccine doses resulted in significantly lower neutralising antibodies but that a third dose of their vaccine increased the neutralising antibodies by a factor of 25.

• Covid-19: Omicron reported in 57 countries; hospitalisations set to rise, says WHO